MedTech Atlas
Back to medical device regulatory guideAll countries
Asia PacificENPublic regulatory overview

Indonesia

Country Overview Market Notes: Indonesia operates a strong distributorled market structure for foreign manufacturers. Fluency in Bahasa Indonesia regulatory requirements and the ab...

Updated: 2026-05-04

You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.

Sign in / register for full country report
Reference approval strategy

FDA / CE / MDSAP / NMPA benefits for this market

These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.

US FDA

510(k) / De Novo / PMAModerate benefit

FDA evidence is useful technical and clinical support, but the local authority still performs an independent review.

Likely benefit
  • Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
  • May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
  • Does not remove local holder, language, labeling, fee, import, or post-market obligations.
View topic

EU CE

MDR / IVDRStrong benefit

CE documentation is highly reusable and may support reference, reliance, or overseas conformity assessment routes.

Likely benefit
  • Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
  • Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
  • Does not replace local registration or local representative responsibilities outside the CE-recognized route.
View topic

MDSAP

Single QMS auditIndirect QMS signal

MDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.

Likely benefit
  • Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
  • Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
  • Does not authorize product sale and does not replace safety, performance, or clinical evidence.
View topic

China NMPA

China registration / filingSupportive evidence

NMPA approval can serve as prior-market evidence and a commercial credibility signal, especially for China-made products.

Likely benefit
  • Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
  • Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
  • Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
View topic

AI Citation Summary

  • Country: Indonesia
  • Product line: Medical devices
  • Regulator / source: Market Notes: Indonesia operates a strong distributor-led market structure for foreign manufacturers. Fluency in Bahasa Indonesia regulatory requirements and the ability to execute locally through a qualified distributor are essential for successful market entry.
  • Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
  • Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
  • Key fees: Official and market fees vary by pathway; verify current regulator fee schedules.
  • Local requirement: Local distributor / AKL holder - Foreign manufacturers usually apply and maintain product licences through a licensed local distributor / importer - Contracts should lock down AKL / NIE control, licence transfer, import permits, PMS, recall, after-sales, termination, and handover
  • Official sources: Official regulator portals and source links are listed in the country report where available.
  • Last verified: 2026-05-04
  • Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
  • Preferred citation: MedTech Atlas

Country Overview

  • Market Notes: Indonesia operates a strong distributor-led market structure for foreign manufacturers. Fluency in Bahasa Indonesia regulatory requirements and the ability to execute locally through a qualified distributor are essential for successful market entry.

Market-Entry Logic

Indonesia medical device entry should be separated into five layers: Kemenkes / Regalkes product licensing, local distributor as AKL / NIE holder, importation and Bahasa Indonesia labeling, LKPP / e-catalogue / JKN public procurement, and TKDN / local-content plus after-sales service. Foreign manufacturers generally cannot control submission and import execution directly; the local distributor's registration, importation, tendering, engineering, and service capability determines the quality of market entry.

Layer Market-entry meaning Operating focus
Kemenkes / Regalkes registration Medical device registration and AKL / NIE product licensing are handled through the Ministry of Health / Kemenkes Regalkes system Verify classification, Regalkes account, file format, authorisation, FSC, ISO 13485, labeling, and renewal requirements before launch
Local distributor / AKL holder Foreign manufacturers usually apply and maintain product licences through a licensed local distributor / importer Contracts should lock down AKL / NIE control, licence transfer, import permits, PMS, recall, after-sales, termination, and handover
Importation, labeling, and customs The local importer manages API / customs / HS code; products sold on the market must meet Bahasa Indonesia label and IFU expectations Label translation, packaging, import documents, samples, customs files, and batch documents should match the registered scope
LKPP / e-catalogue / JKN Public hospitals, JKN/BPJS, and government procurement channels are influenced by e-catalogue access, pricing, and supply continuity Prepare tender eligibility, e-catalogue access, pricing, supply capability, and hospital access in parallel with registration
TKDN / localisation and service Government procurement increasingly values local content, assembly, service capability, and long-term maintenance Assess TKDN impact, local assembly, spare-parts depot, engineers, training, and SLA

For foreign manufacturers, Indonesia is not a simple "get AKL then sell" market. AKL/NIE is the compliance entry point; e-catalogue, TKDN, hospital access, after-sales engineering, and distributor control are the variables behind scale.

Main Players and Channel Map

Player type Representative institutions / companies Commercial meaning
Regulator Ministry of Health / Kemenkes, Farmalkes / Regalkes Core entry point for device product licences, AKL / NIE, registration maintenance, and local-distributor responsibility
Public procurement and payer LKPP / e-catalogue, BPJS Kesehatan / JKN, public hospital system Government procurement, catalogue access, pricing, supply continuity, and public-hospital volume
Local distributors / importers Medical equipment, IVD, consumables, dental, imaging, and hospital-engineering distributors Execute registration, importation, tenders, installation, maintenance, training, spare parts, and cash collection
Hospital groups and diagnostic networks Siloam Hospitals, Mitra Keluarga, Hermina, Mayapada, Primaya, Prodia, and others Early reference sites for mid-to-high-end equipment, IVD, imaging, consumables, and private channels
Multinational device companies Siemens Healthineers, GE HealthCare, Philips, Medtronic, Abbott, Roche Diagnostics, BD, Stryker, and others Premium equipment, IVD, consumables, clinical education, after-sales service, and key-account management
Local manufacturing / assembly ecosystem Basic consumables, hospital furniture, simple devices, packaging, service, and potential assembly partners Supports TKDN, localisation, government-procurement preference, and price competition

Channel due diligence should separately verify whether the distributor can actually maintain AKL/NIE; whether it can access LKPP / e-catalogue and target hospitals; whether it has engineers, spare parts, application training, and service SLAs; and whether it can handle importation, FX, inventory, and government payment cycles.

  1. Kemenkes digital licensing continues to strengthen: Regalkes / AKL / NIE is the foundational device-entry system, and account, licence-holder, and transfer arrangements affect long-term commercial control.
  2. e-catalogue and JKN raise public-channel thresholds: Public hospital procurement increasingly values price, supply continuity, compliant catalogue access, and local service. Registration approval alone is not enough to create government volume.
  3. TKDN and localisation influence government procurement: Local content, assembly, service, and supply-chain commitments affect competitiveness in government projects, especially for basic devices, consumables, and standard equipment.
  4. After-sales service becomes a premium-device access condition: Imaging, IVD, surgical, ICU / OR, and dental equipment require installation, calibration, maintenance, spare parts, and clinical-application support.
  5. Private hospitals and diagnostic networks are useful reference sites: Private channels are more flexible and can serve as early reference sites for innovative devices, premium equipment, and diagnostic products.
  6. Distributor-control risk is significant: If the distributor controls AKL/NIE, import permits, and customer relationships, later distributor changes, certificate transfer, and supply continuity may depend heavily on contract terms.

Regulatory Authority

  • Primary Authority: Ministry of Health (Kementerian Kesehatan / Kemenkes), especially the medical devices and household health supplies directorate / Farmalkes function
  • Submission Portal: Regalkes (https://regalkes.kemkes.go.id)
  • Key local terms: AKL / NIE product licence, local distributor / importer, Bahasa Indonesia labeling, LKPP / e-catalogue, TKDN

Device Classification System

Local Class Risk Level Approximate EU Equivalent Notes
A Low Class I Basic, low-risk devices
B Low-Moderate Class IIa General medical devices
C Moderate-High Class IIb Higher-risk devices requiring more extensive documentation
D High Class III Highest risk; most stringent review requirements

Registration Pathways

During the limited-time free period, sign in or register to view the complete medical device country report.